PharmAthene, Inc. PIP announced today that it has achieved an important technical milestone in its recombinant protective antigen anthrax vaccine program. PharmAthene has successfully completed initial technology transfer of its manufacturing process for the bulk drug substance of its vaccine candidate, SparVax™, at the 100 liter scale to a US-based manufacturing facility at Diosynth RTP.
Activities to scale-up production to the final commercial 1,500 liter scale are underway.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in